Objective:

To evaluate the effectiveness of a blood-based liquid biopsy for diagnosing EBV-positive Burkitt’s lymphoma in resource-limited settings, highlighting its significance in improving patient outcomes.

Approach:

Key Findings:

• Liquid biopsy showed high diagnostic accuracy with sensitivity of 0.86 and specificity of 0.95, similar performance observed in an independent validation group.
• Results from liquid biopsy were available in a median of 6.5 days compared to 46.8 days for tissue biopsy.
• 42% of cases had liquid biopsy results available at the first multidisciplinary team review, aiding early diagnosis.

Interpretation:

Liquid biopsy may provide faster and earlier diagnostic information for Burkitt’s lymphoma, particularly in areas with limited access to pathology services, potentially improving patient outcomes.

Limitations:

• Variability in diagnostic methods across different sites.
• Use of a simplified IHC panel as the reference standard.
• Need for further validation in broader populations, along with addressing implementation challenges such as cost and access to sequencing infrastructure.

Conclusion:

While tissue biopsy remains essential for full classification, liquid biopsy can enhance early diagnosis and guide clinical decisions in resource-limited settings, emphasizing its role in improving patient care.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.